Outsourcing STREAM

  1. How MilliporeSigma Promotes Quality And Risk Reduction 10/20/2021

    Learn how MilliporeSigma’s new facility was built with quality and risk reduction at the top of mind and its experts have the experience to support large-scale programs through commercialization.

  2. Factors Which Impact mAb Process Scale-Up 9/7/2021

    Thinking about your mAb scale-up processes early on can help avoid common pitfalls. Cytiva’s Fast Trak scientists discuss factors that can influence a successful scale-up outcome.

  3. Thermo Fisher Scientific China Single-Use Technologies Capacity Expansion 3/2/2021

    Thermo Fisher Scientific is expanding our single-use manufacturing network globally. With continuous growth in China’s population, we have seen an increase in demand for human therapeutics and vaccines and an even greater need for investment in public health and safety to develop biopharmaceutical products in China.

  4. The Journey To Safety Through Viral Clearance 12/1/2022

    Discover a simple yet powerful solution for getting viral clearance studies done safely, thoroughly, efficiently, and on your timelines. Learn how to free your teams and trust your project.

  5. Combining Expertise With Best-In-Class Technology 10/20/2021

    Members of the MilliporeSigma leadership team reflect on the longstanding experience of our BioReliance® viral vector manufacturing facilities. Our legacy experience, alongside our brand new facility and latest industry innovations, ensure we are a preferred partner to pioneer the path to cures.

  6. Thermo Fisher Scientific North America Single-Use Technologies Capacity Expansion 3/2/2021

    Thermo Fisher Scientific is expanding our single-use manufacturing network globally. Some of the largest investments are taking place at our existing Logan, Utah, and Millersburg, Pennsylvania, sites. We are adding space for clean rooms for the manufacturing and assembly of Thermo Scientific BioProcess Containers and fluid transfer assemblies, investing in 2D and 3D chamber manufacturing equipment, and harmonizing our quality systems and processes.

  7. Level Up With Product Characterization 3/12/2021

    In the race to bring a new biotherapeutic to market, unexpected obstacles can slow you down or even knock you back a few steps. But with the right information at the right time, and an experienced partner to provide scientific, regulatory, and bioprocessing guidance and support, you can find a smoother, faster path to the finish line.

  8. Collaboration & Expertise, The Keys To Efficiency And Scalability Across All Modalities 7/8/2022

    View this video and discover our global vaccine capabilities from process development to full-scale GMP-manufacturing and in all modalities.

  9. M Lab™ Collaboration Centers Video 9/1/2022

    M Lab™ Collaboration Centers is a network comprised of scientific experts, innovative technologies, and flexible non-GMP facilities where you can troubleshoot your process, identify efficiencies, and adopt innovative techniques.

  10. Increasing The Reach Of Cell And Gene Therapies 4/29/2021

    The cell and gene therapy industry is rapidly evolving from the perspective of “can we commercialize this class of therapeutics?” to “how do we reach patients who need these therapies?”. However, the promise of these biologics can only be realized if the industry approaches manufacturing parity with monoclonal antibodies. A mixture of innovation and brute-force streamlining is needed to create viable cell and gene therapy templates. In this video, we discuss how upstream process optimization is ripe for innovative approaches.